Literature DB >> 20001801

Pathogenesis of ovarian cancer: clues from selected overexpressed genes.

Ie-Ming Shih1, Ben Davidson.   

Abstract

Ovarian cancer is the most malignant gynecologic neoplasm. Although new chemotherapeutic agents have improved patients' 5-year survival rate, the overall mortality of ovarian cancer has remained largely unchanged in the past several decades. The main reason for the lack of success in effectively treating ovarian cancer is our limited understanding of its etiology and the very few molecular diagnostic markers and therapeutic targets known so far. Identification and characterization of ovarian cancer-associated genes are fundamental for unveiling the pathogenesis of its initiation and progression, especially the development of recurrent diseases. As there are a vast number of genes for which molecular genetic changes and aberrant gene expression have been reported in ovarian cancer, this review will only focus on summarizing those exemplified genes that have been demonstrated to have biological functions in promoting ovarian cancer development and potential clinical significance. The genes to be discussed include nuclear proteins (Notch3, HBXAP [Rsf-1], NAC1 and NFkappaB), cytoplasmic proteins (fatty acid synthase and apolipoprotein E) and cell surface/secretory proteins (mucin-4, mesothelin, claudin, HLA-G, kallikrein and folate receptor and osteopontin). Since the study of ovarian cancer-associated genes is complicated by several factors unique to ovarian cancer, we will also present our views on the limitations and challenges of current ovarian cancer research.

Entities:  

Mesh:

Year:  2009        PMID: 20001801      PMCID: PMC2821471          DOI: 10.2217/fon.09.126

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  132 in total

Review 1.  Fatty acid synthase and cancer: new application of an old pathway.

Authors:  Francis P Kuhajda
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

2.  BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.

Authors:  David D Gibbs; Davinder S Theti; Nadya Wood; Matthew Green; Florence Raynaud; Melanie Valenti; Martin D Forster; Fraser Mitchell; Vassilios Bavetsias; Elisa Henderson; Ann L Jackman
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

Review 3.  Claudin proteins in human cancer: promising new targets for diagnosis and therapy.

Authors:  Patrice J Morin
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

4.  Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels.

Authors:  Jennifer J Stewart; James T White; Xiaowei Yan; Steven Collins; Charles W Drescher; Nicole D Urban; Leroy Hood; Biaoyang Lin
Journal:  Mol Cell Proteomics       Date:  2005-11-30       Impact factor: 5.911

Review 5.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

6.  Potential markers that complement expression of CA125 in epithelial ovarian cancer.

Authors:  Daniel G Rosen; Lin Wang; J Neeley Atkinson; Yinhua Yu; Karen H Lu; Eleftherios P Diamandis; Ingegerd Hellstrom; Samuel C Mok; Jinsong Liu; Robert C Bast
Journal:  Gynecol Oncol       Date:  2005-08-02       Impact factor: 5.482

7.  The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms.

Authors:  Heather C Workman; Colleen Sweeney; Kermit L Carraway
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

8.  Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.

Authors:  Cynthia Kuk; Vathany Kulasingam; C Geeth Gunawardana; Chris R Smith; Ihor Batruch; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2008-12-01       Impact factor: 5.911

9.  Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.

Authors:  M Jim Yen; Chih-Yi Hsu; Tsui-Lien Mao; T-C Wu; Richard Roden; Tian-Li Wang; Ie-Ming Shih
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

10.  Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours.

Authors:  Arne Westgaard; Aasa R Schjølberg; Milada Cvancarova; Tor J Eide; Ole Petter F Clausen; Ivar P Gladhaug
Journal:  Histopathology       Date:  2009-02       Impact factor: 5.087

View more
  22 in total

1.  DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin.

Authors:  A Mitra; M E Menezes; L K Pannell; M S Mulekar; R E Honkanen; L A Shevde; R S Samant
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

2.  Prognostic value of rsf-1/hbxap in human solid tumors: a meta-analysis of cohort studies.

Authors:  Jiayuan Wu; Liren Hu; Fenping Wu; Taiping He
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  MKK4 acts as a potential tumor suppressor in ovarian cancer.

Authors:  Shamima Yeasmin; Kentaro Nakayama; Mohammed Tanjimur Rahman; Munmun Rahman; Masako Ishikawa; Atsuko Katagiri; Kouji Iida; Naomi Nakayama; Kohji Miyazaki
Journal:  Tumour Biol       Date:  2011-04-14

4.  Perinatal exposure to low-dose DE-71 increases serum thyroid hormones and gonadal osteopontin gene expression.

Authors:  Charles A Blake; George L McCoy; Yvonne Y Hui; Holly A LaVoie
Journal:  Exp Biol Med (Maywood)       Date:  2011-03-02

5.  p53 protein aggregation promotes platinum resistance in ovarian cancer.

Authors:  Y Yang-Hartwich; M G Soteras; Z P Lin; J Holmberg; N Sumi; V Craveiro; M Liang; E Romanoff; J Bingham; F Garofalo; A Alvero; G Mor
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

6.  Downregulation of human epidermal growth factor receptor 2 by short hairpin RNA increases chemosensitivity of human ovarian cancer cells.

Authors:  Li Shan Ma; Q I Yan; Yongfang Huang; Wenxia Zhao; Y U Zhu
Journal:  Oncol Lett       Date:  2015-03-12       Impact factor: 2.967

7.  Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma.

Authors:  Daichi Maeda; Xu Chen; Bin Guan; Shunsuke Nakagawa; Tetsu Yano; Yuji Taketani; Masashi Fukayama; Tian-Li Wang; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2011-01       Impact factor: 2.762

8.  Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development.

Authors:  Jim Jinn-Chyuan Sheu; Jung Hye Choi; Bin Guan; Fuu-Jen Tsai; Chun-Hung Hua; Ming-Tsung Lai; Tian-Li Wang; Ie-Ming Shih
Journal:  J Pathol       Date:  2013-02-04       Impact factor: 7.996

9.  RanBPM expression regulates transcriptional pathways involved in development and tumorigenesis.

Authors:  Elnaz Atabakhsh; Jean H Wang; Xu Wang; David E Carter; Caroline Schild-Poulter
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

10.  miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6.

Authors:  Weiwei Shan; Jun Li; Yang Bai; Xin Lu
Journal:  Tumour Biol       Date:  2015-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.